Abstract 293P
Background
Cervical cancer is a global public health issue. Cisplatin-based chemoradiation is the standard treatment for locally advanced scenarios. However, the toxicity and prolonged infusion time associated with cisplatin necessitate the search for options that yield similar outcomes. The objective of this study will be to compare the effectiveness of carboplatin versus cisplatin in patients with locally advanced cervical cancer undergoing chemoradiation.
Methods
The current study is an observational, retrospective, longitudinal, and descriptive type of research. The sample consisted of 183 patients with locally advanced cervical cancer who underwent chemoradiation treatment at the National Institute of Neoplastic Diseases, Lima, Peru, in the years 2014-201.
Results
Ninety-five patients aged equal to or less than 50 years and 88 patients aged over 50 years were analyzed, corresponding to 52% and 48% of the sample, respectively. The squamous cell carcinoma subtype represented 90% of the sample (164 cases), and the most frequent stages were IIB and IIIC, at 64% and 27% respectively. The trend for complete responses was higher for cisplatin, 82% vs. 77% for carboplatin. Patients who received cisplatin experienced more adverse effects than those who received carboplatin; neutropenia, diarrhea, and vomiting were the most reported events. At a 5-year follow-up, there was a 41% reduction in the risk of recurrence for cisplatin treatment (p 0.055), with a hazard ratio for overall survival of 0.72. It was observed that those who achieved a complete response had better survival.
Conclusions
In summary, while cisplatin demonstrated greater efficacy in terms of overall survival, carboplatin stood out for its more favorable tolerance profile. This suggests that carboplatin could be a valid alternative for patients with a more delicate clinical condition who might face challenges with cisplatin-associated toxicity. These findings underscore the importance of considering both efficacy and tolerability when choosing the appropriate therapy for patients with locally advanced cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
N. Valdiviezo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract